Related Articles
Astragaloside IV ameliorates diabetic nephropathy in <em>db/db</em> mice by inhibiting NLRP3 inflammasome‑mediated inflammation
Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6
Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF‑β1/Smad/miR‑192 signaling pathway
Astragaloside Ⅳ combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway
Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment